Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.70 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.62 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.62 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181645 | 1.00 | CHRNB4 (0.70) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL3123997 | 0.91 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL8437647 | 0.81 | CHRNB4 (0.97) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL7368969 | 0.77 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL30881547 | 0.77 | CHRNB4 (0.61) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL8437748 | 0.76 | CHRNB4 (0.97) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL906007 | 0.76 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL7055867 | 0.76 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNA4 | |
| SCHEMBL5585295 | 0.75 | KDM4E (0.52) | CHRNB2CHRNA4 | |
| SCHEMBL3114012 | 0.74 | LRRK2 (0.47) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | CHRNB4 115/4885CHRNA3 182/4885CHRNB1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.